Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: ELISA quantification of CD5L ( A ), CLU ( B ), and SERPINF1 ( C ) protein levels in the vitreous humor of DR and Control patients. * p < 0.05, **** p < 0.0001.

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Enzyme-linked Immunosorbent Assay, Control

Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: Immunohistochemical analysis of CD5L, CLU, and SERPINF1 expression. Immunohistochemical analysis of CD5L, CLU, and SERPINF1 expression in whole-retinal and retinal nerve fiber layer from DR and control SD rats. Images were acquired at 40×magnification, full-field view; scale bar, 25 μm. Nuclei are counterstained blue, and positive staining for CD5L, CLU, and SERPINF1 appears brown. ** p < 0.01, *** p < 0.001.

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Immunohistochemical staining, Expressing, Control, Staining

Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: Prediction of Transcription factors (TFs) and modification sites in key proteins. ( A ) Transcription factor prediction of key proteins. ( B ) Prediction results of PTM sites of key protein APLP2. ( C ) Prediction results of PTM sites of key protein RBP3. ( D ) Prediction results of PTM sites of key protein SERPINF1. ( E ) Prediction results of acetylation of key protein CLU. ( F ) Prediction results of acetylation of key protein PSAP. ( G ) Prediction results of phosphorylation, acetylation, ubiquitination of key protein C5. ( H ) Prediction results of key protein CD5L.

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Modification, Phospho-proteomics, Ubiquitin Proteomics

Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: Prediction of drug candidates targeting key proteins and functional effects of exogenous CD5L on endothelial cells. ( A ) Molecular docking diagram of key protein RBP3 and drug VITAMIN A PALMITATE. ( B ) Molecular docking diagram of key protein RBP3 and drug VITAMIN A PALMITATE. The purple is the key protein, the iridescent is the drug, and the yellow dotted line is the hydrogen bond between the two, as well as the corresponding bond length and residue. ( C ) EdU assay showing the effect of CD5L on C166 cell proliferation.(Images are shown at 10×magnification, scale bar, 2 μm, proliferating cells are indicated by green fluorescence (EdU), ** p <0.01). ( D ) Scratch wound assay showing the effect of CD5L on C166 cell migration (* p <0.05).

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Functional Assay, Residue, EdU Assay, Fluorescence, Scratch Wound Assay Assay, Migration

Journal: Biochemical and biophysical research communications

Article Title: CD5L is a target of transcription factor Nrf2.

doi: 10.1016/j.bbrc.2025.152225

Figure Lengend Snippet: Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

Article Snippet: Human rCD5L (2797-CL, R&D Systems) was reconstituted in sterile PBS.

Techniques: Recombinant

Journal: Frontiers in Immunology

Article Title: Gas6 induces AIM to suppress acute lung injury in mice by inhibiting NLRP3 inflammasome activation and inducing autophagy

doi: 10.3389/fimmu.2025.1523166

Figure Lengend Snippet: The Gas6–Axl–LXRα/β signaling pathway inhibits NLRP3 inflammasome activation in BMDMs by promoting AIM production. ELISA was performed to quantify the abundance of IL-1β (A, E, H, K) and IL-18 (B, F, I, L) in culture supernatants of bone marrow-derived macrophages (BMDMs). (C, G, J, M) Caspase-1 activity was measured in culture supernatants of BMDMs. (D) Left: Representative immunofluorescence confocal microscopic images of ASC specks (green). Arrows point to ASC specks. Original magnification: 200 ×. Scale bars: 50 μm. Right: Quantification of the percentage of cells with ASC specks (4 × 200 cells/nuclei [DAPI-stained], analyzed with ImageJ). BMDMs were transfected with two types of siRNAs for AIM (A–D) , LXRα (E–G) , LXRβ (H–J) , or Axl (K–M) and then treated with rGas6 (100 ng/ml) or rAIM (1 μg/ml) for 24 h, followed by LPS (100 ng/ml) for 4 h and ATP [1 mM in (A–C) and (E–M) or 5 mM in (D) ] for 1 h. Values represent the mean ± standard error of three (A–C) , (E–M) or four (D) independent experiments. NS, not significant; *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control or as indicated.

Article Snippet: Mouse rGas6 (986-GS), mouse recombinant AIM (rAIM) (2834-CL-050), LPS ( Escherichia coli serotype 055:B5, L2880), and adenosine 5’-triphosphate disodium salt (A6419) were acquired from R&D Systems (Minneapolis, MN, USA).

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Derivative Assay, Activity Assay, Immunofluorescence, Staining, Transfection, Control

Journal: Autoimmunity

Article Title: CD5L induces inflammation and survival in RA-FLS through ERK1/2 MAPK pathway.

doi: 10.1080/08916934.2023.2201412

Figure Lengend Snippet: Figure 2. CD5L induced the expression of inflammatory factors in RA-FLS. The cells were stimulated with different concentrations of recombinant CD5L (0, 50, 100, 200, 500, 1000 ng/mL) for 24 h. (A) The levels of IL-6, IL-8, and TNF-α in cell culture supernatant were detected by ELISA. (B) mRNA levels of IL-6, IL-8, and TNF-α were detected by RT-PCR. (C) The levels of IL-6, IL-8, and TNF-α in cell culture supernatant after stimulating different time. (D) mRNA levels of IL-6, IL-8, and TNF-α after stimulating different time. The concentration of CD5L for stimulation was 500 ng/mL. Compared with the control group (0 ng/mL), ns, no statistical difference; *p < 0.05, **p < 0.01, ***p < 0.001. The measurements were repeated three times for each group of data.

Article Snippet: Materials Recombinant human CD5L protein was purchased from R&D Systems (Minneapolis, USA).

Techniques: Expressing, Recombinant, Cell Culture, Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Concentration Assay, Control

Journal: Autoimmunity

Article Title: CD5L induces inflammation and survival in RA-FLS through ERK1/2 MAPK pathway.

doi: 10.1080/08916934.2023.2201412

Figure Lengend Snippet: Figure 3. CD5L activated ERK1/2 MAPK signaling pathway. Cells (5 × 106) were challenged with CD5L protein (500 ng/mL) for different times(0, 30, 60, 90 min). The protein was extracted and the expression levels of phosphorylation signal molecules (A) p-p38 MAPK, p-AKT, p-JAK, and p-I κB-α and (B) p-ERK were detected by WB.

Article Snippet: Materials Recombinant human CD5L protein was purchased from R&D Systems (Minneapolis, USA).

Techniques: Expressing, Phospho-proteomics

Journal: Autoimmunity

Article Title: CD5L induces inflammation and survival in RA-FLS through ERK1/2 MAPK pathway.

doi: 10.1080/08916934.2023.2201412

Figure Lengend Snippet: Figure 4. Effect of inhibitor on CD5L-induced inflammatory-related factors in RA-FLS. The cells were pretreated with inhibitor U0126 for 1 h and cultured for 24 h with or without CD5L. The optimum concentration of U0126 deter mined by pre-experiment is 16 μM. (A) The expression levels of IL-6, IL-8, and TNF-α in the supernatant of cell culture were detected by ELISA. (B) mRNA levels of IL-6, IL-8, and TNF-α were detected by RT-PCR. Results of three independent replicates were expressed as mean ± standard deviation. Figure 4. Continued.

Article Snippet: Materials Recombinant human CD5L protein was purchased from R&D Systems (Minneapolis, USA).

Techniques: Cell Culture, Concentration Assay, Expressing, Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Standard Deviation

Journal: Autoimmunity

Article Title: CD5L induces inflammation and survival in RA-FLS through ERK1/2 MAPK pathway.

doi: 10.1080/08916934.2023.2201412

Figure Lengend Snippet: Figure 6. Effects of CD5L on apoptosis and proliferation of RA-FLS. Cells with inhibitor U0126 were pretreated for 1 h and cultured for 24 h with or without CD5L. (A) mRNA levels of BAX and BCL2 were detected by RT-PCR; (B) BAX and BCL-2 protein levels were detected by WB. (C) CCK-8 kit was used to detect the proliferation ability of RA-FLS. The blank wells contained only culture medium, and the control wells contained cells and culture medium. The exper imental results were expressed as mean ± standard deviation.

Article Snippet: Materials Recombinant human CD5L protein was purchased from R&D Systems (Minneapolis, USA).

Techniques: Cell Culture, Reverse Transcription Polymerase Chain Reaction, CCK-8 Assay, Control, Standard Deviation

Journal: Autoimmunity

Article Title: CD5L induces inflammation and survival in RA-FLS through ERK1/2 MAPK pathway.

doi: 10.1080/08916934.2023.2201412

Figure Lengend Snippet: Figure 5. Effect of inhibitor on CD5L activation of ERK1/2 MAPK signaling pathway. Cells (5 × 106) were treated with ERK1/2 inhibitor U0126 for 1 h, and then added CD5L protein for 90 min. Protein was extracted, and the expression level of phosphorylated signal molecule p-ERK1/2 MAPK was detected by WB. GAPDH was used to correct the protein content of each sample.

Article Snippet: Materials Recombinant human CD5L protein was purchased from R&D Systems (Minneapolis, USA).

Techniques: Activation Assay, Expressing